12.3 Short Bowel Syndrome & Intestinal Failure

12.3 Short Bowel Syndrome & Intestinal Failure

Clinical Core: Short Bowel Syndrome (SBS) is the leading cause of chronic intestinal failure (CIF), resulting from extensive surgical resection, congenital defect, or disease-associated loss of small bowel. Absorptive capacity depends on the length and specific anatomy of the remaining bowel segments. The ileum and colon possess critical, non-redundant physiological adaptations: the ileum mediates bile acid and vitamin B12 absorption and secretes trophic enterohormones (GLP-1, GLP-2, PYY), while the colon provides colonic energy salvage (500 to 1000 kcal/day via short-chain fatty acids) and avid water reabsorption. Patients with a colon in continuity face distinct risks of calcium oxalate nephrolithiasis and D-lactic acidosis. Hydration relies on high-sodium oral rehydration solutions (ORS, ~90 mEq/L Na) utilizing SGLT-1 co-transport, while recombinant GLP-2 analogs (teduglutide) stimulate crypt proliferation to facilitate parenteral weaning.

Anatomical Definitions & Diagnostic Thresholds

The normal functional length of the adult small intestine ranges from $300\text{ to } 600\text{ cm}$ (measured from the duodenojejunal flexure at the ligament of Treitz to the ileocecal valve). Intestinal failure occurs when functional absorptive surface area is insufficient to maintain fluid, electrolyte, and macronutrient balance without parenteral or specialized enteral support.

Clinical Definitions of SBS

• Without a Colon-in-Continuity (End-Jejunostomy): Residual small intestine measuring $< 150\text{ to } 200\text{ cm}$ terminating in a stoma.
• With a Colon-in-Continuity (Jejuno-Colic or Jejuno-Ileal): Residual small intestine measuring $< 60\text{ to } 100\text{ cm}$ anastomosed to a functional colon.

+-----------------------------------------------------------------------------------------+
|                         THREE ANATOMICAL PATTERNS OF SBS                                |
+-----------------------------------------------------------------------------------------+
| Anatomic Type         | Remaining Segments       | ICV & Colon? | Clinical Prognosis    |
| --------------------- | ------------------------ | ------------ | --------------------- |
| End-Jejunostomy       | Jejunum only             | Absent       | Poor; massive fluid / |
| (Type 1)              | (Stoma to skin)          |              | sodium losses; high PN|
| --------------------- | ------------------------ | ------------ | --------------------- |
| Jejuno-Colic          | Jejunum anastomosed      | Absent       | Intermediate; colon   |
| (Type 2)              | to partial/full colon    |              | salvages fluid & SCFA;|
|                       |                          |              | oxalate stone risk    |
| --------------------- | ------------------------ | ------------ | --------------------- |
| Jejuno-Ileal          | Jejunum + distal ileum   | Preserved    | Favorable; ileum      |
| (Type 3)              | anastomosed to colon     | (ICV intact) | adapts; rarely needs  |
|                       |                          |              | permanent PN if >35 cm|
+-----------------------------------------------------------------------------------------+

---

Segmental Physiology & Intestinal Adaptation

Understanding the distinct physiological functions of each intestinal segment is essential for designing nutrition support regimens in this independent study resource:

+-----------------------------------------------------------------------------------------+
|                    FUNCTIONAL COMPARISON OF INTESTINAL SEGMENTS                         |
+-----------------------------------------------------------------------------------------+
| Parameter        | Jejunum                  | Ileum                  | Colon            |
| ---------------- | ------------------------ | ---------------------- | ---------------- |
| Primary Function | Macronutrient absorption | B12 & bile acid uptake | Water & Na+      |
|                  | (protein, fat, CHO)      | Enterohormone release  | SCFA absorption  |
| Motility Transit | Rapid transit            | Slow ("Ileal brake")   | Slow ("Colonic   |
|                  |                          | (via PYY, GLP-1)       | brake")          |
| Tight Junctions  | "Leaky" (permeable)      | Tight (impermeable)    | Very tight        |
| Structural       | Minimal compensatory     | Pronounced hypertrophy | Mucosal colonic  |
| Adaptation       | hyperplasia              | (villi lengthen 50%+)  | hyperabsorption  |
+-----------------------------------------------------------------------------------------+

1. The Jejunum

• Absorptive Capacity: The jejunum possesses tall villi and high concentrations of brush border enzymes, absorbing the bulk of dietary carbohydrates, proteins, water-soluble vitamins, calcium, magnesium, and iron.
• Permeability: Intercellular tight junctions in the jejunum are large and "leaky." Osmotic gradients drive rapid water movement across the mucosa.
• Adaptation: The jejunum does not undergo significant structural adaptation following distal resection. If the ileum is lost, the jejunum cannot increase its villus height or transit time to compensate.

2. The Ileum

• Non-Redundant Specialized Functions:
  1. Vitamin B12 Absorption: Intrinsic factor-B12 complexes are absorbed exclusively in the terminal $50\text{ to } 100\text{ cm}$ of the ileum via cubilin receptors. Resection mandates lifelong parenteral cyanocobalamin supplementation ($1000\text{ mcg}$ IM monthly).
  2. Bile Acid Absorption: Active reabsorption of conjugated bile acids occurs exclusively in the distal $100\text{ cm}$ of the ileum via the apical sodium-dependent bile acid transporter (ASBT).
• The Ileal Brake: Presence of unabsorbed fat and carbohydrate in the distal ileum triggers endocrine L-cells to secrete Peptide YY (PYY) and Glucagon-Like Peptide-1 (GLP-1). These peptides inhibit proximal gastric emptying and slow small bowel transit (the ileal brake), maximizing contact time for nutrient absorption.
• Profound Adaptation: Unlike the jejunum, the ileum possesses dramatic adaptive capacity. After proximal jejunal resection, the ileum undergoes marked structural hyperplasia over $12\text{ to } 24\text{ months}$: villus height increases, crypt depth deepens, transporter expression upregulates, and luminal diameter dilates, increasing absorptive capacity multiple-fold.

3. The Colon

• Water and Sodium Absorption: An intact, adapted colon can absorb up to $5\text{ to } 6\text{ liters}$ of water and $800\text{ mEq}$ of sodium per day, compared to a baseline capacity of $1.5\text{ to } 2.0\text{ L/day}$.
• Colonic Energy Salvage via Short-Chain Fatty Acids (SCFAs): Anaerobic colonic microflora ferment unabsorbed complex carbohydrates and soluble fibers into SCFAs (acetate, propionate, butyrate). Colonocytes absorb SCFAs via active sodium-coupled monocarboxylate transporters (SMCT-1). This colonic fermentation salvages $500\text{ to } 1000\text{ kcal/day}$, effectively functioning as an auxiliary digestive organ.

---

Pathophysiology of SBS Complications

+-------------------------------------------------------------------------+
|               UNIQUE PATHOLOGY IN SBS WITH COLON-IN-CONTINUITY          |
+-------------------------------------------------------------------------+
| 1. CALCIUM OXALATE NEPHROLITHIASIS:                                     |
| Luminal Fat Malabsorption ---> Fatty Acids Bind Calcium (Saponification)|
| ---> Unbound Free Oxalate Floods Colon ---> Hyperabsorbed into Blood    |
| ---> Renal Oxalate Excretion Exceeds Solubility ---> OXALATE STONES     |
| ----------------------------------------------------------------------- |
| 2. D-LACTIC ACIDOSIS:                                                   |
| Malabsorbed Simple Sugars Enter Colon ---> Lactobacillus Fermentation   |
| ---> D-Lactate Produced (Colonic pH < 5.5) ---> Systemic Absorption     |
| ---> Human LDH Cannot Metabolize D-Lactate ---> METABOLIC ENCEPHALOPATHY|
+-------------------------------------------------------------------------+

1. Gastric Hypersecretion

• Mechanism: Resection of distal intestine eliminates negative feedback enterohormones (secretin, somatostatin, GLP-1, PYY) on gastric parietal cells, causing temporary, massive gastric hypersecretion of hydrochloric acid.
• Consequences: The hyperacidic gastric effluent inundates the proximal small bowel, denaturing pancreatic lipase and trypsin, precipitating luminal bile salts, and causing mucosal peptic injury.
• Management: High-dose proton pump inhibitors (e.g., omeprazole or pantoprazole $40\text{ mg}$ IV/PO BID) or H2-receptor antagonists during the first $6\text{ to } 12\text{ months}$ post-resection.

2. Calcium Oxalate Nephrolithiasis (Enteric Hyperoxaluria)

• Prerequisite: Occurs exclusively in patients with an intact colon and fat malabsorption (Type 2 and Type 3 SBS). Patients with an end-jejunostomy do not develop enteric hyperoxaluria because they lack a colon.
• Mechanism: In healthy adults, dietary calcium binds dietary oxalate in the small intestine to form an insoluble, unabsorbable salt (calcium oxalate), which is excreted in the stool. In SBS, unabsorbed free fatty acids enter the colon and bind luminal ionized calcium with high affinity (saponification). With calcium bound to fatty acids, dietary oxalate remains free, soluble, and unbound. Concurrently, unabsorbed bile salts and fatty acids increase colonic mucosal permeability to oxalate. Free oxalate is rapidly absorbed across the colonic mucosa into circulation and excreted by the kidneys, where it precipitates as calcium oxalate nephrolithiasis.
• Clinical Prevention & Therapy:
  • Low-oxalate diet: Restrict foods rich in oxalate (spinach, rhubarb, beets, nuts, chocolate, black tea).
  • Oral calcium supplementation: Administer calcium carbonate or calcium citrate ($500\text{ to } 1000\text{ mg}$ with meals) to bind free dietary oxalate within the intestinal lumen.
  • Low-fat diet: Limit dietary fat ($20\%\text{ to } 30\%$ of calories) to minimize fatty acid delivery to the colon.

3. D-Lactic Acidosis

• Prerequisite: Occurs in patients with an intact colon consuming excessive refined carbohydrates or simple sugars.
• Mechanism: Unabsorbed simple carbohydrates flood the colon, lowering colonic luminal pH ($< 5.5$). Acid-tolerant anaerobic bacteria (such as Lactobacillus acidophilus) proliferate and ferment carbohydrate into the D-isomer of lactic acid (D-lactate).
• Metabolic Conflict: Human lactate dehydrogenase is stereospecific for L-lactate and cannot rapidly metabolize D-lactate. D-lactate accumulates in the blood, cross-reacting with cerebellar and cerebral receptors.
• Clinical Presentation: Episodic confusion, slurred speech, profound ataxia, aggressive behavior, and blurred vision, resembling acute ethanol intoxication in a patient who has consumed no alcohol. Laboratory evaluation demonstrates a high-anion-gap metabolic acidosis with normal blood L-lactate concentrations (specialized enzymatic assays are required to detect D-lactate).
• Therapy: Strict restriction of refined simple sugars, oral non-absorbable antibiotics (metronidazole, vancomycin, or neomycin) to suppress D-lactate-producing colonic flora, and intravenous sodium bicarbonate.

---

Medical & Nutritional Therapy: Hydration & Diet

The Oral Rehydration Solution (ORS) Paradigm

A frequent error is allowing SBS patients to consume plain water, tea, or soda to satisfy thirst. In patients with an end-jejunostomy, the leaky jejunal tight junctions allow water to move freely down osmotic gradients:

• The Paradox of Plain Water: Ingesting hypotonic plain water creates an osmotic gradient that pulls sodium and water out of extracellular fluid into the intestinal lumen, converting the stoma into a net secretory organ and precipitating catastrophic hypovolemic shock and hyponatremia.
• The SGLT-1 Cotransporter: To achieve net fluid absorption, oral fluids must exploit the intact sodium-glucose cotransporter 1 (SGLT-1) on the jejunal brush border. SGLT-1 actively transports two sodium ions and one glucose molecule across the enterocyte membrane, generating a powerful electrochemical osmotic gradient that drags water molecules along through aquaporin channels:

$2\text{ Na}^+ + 1\text{ Glucose} \xrightarrow{\text{SGLT-1}} \text{Intracellular Transport} \implies \text{Equimolar Water Absorption}$

• ORS Composition: Effective oral rehydration solutions (such as WHO-ORS or specialized commercial/homemade formulations) must be isotonic or slightly hypotonic ($280\text{ to } 300\text{ mOsm/kg}$) with a high sodium concentration of approximately $90\text{ mEq/L}$ and a glucose concentration of $100\text{ to } 120\text{ mmol/L}$ (a 1:1 or 2:1 sodium-to-glucose ratio). Commercial sports drinks have too little sodium ($15\text{--}20\text{ mEq/L}$) and excessive hypertonic sugar ($300\text{--}400\text{ mOsm/L}$), exacerbating stomal losses.

Dietary Principles by Anatomic Reconstruction

---

Pharmacological Optimization: GLP-2 Analog (Teduglutide)

Mechanism of Action

Teduglutide (Gattex) is a recombinant analogue of human glucagon-like peptide-2 (GLP-2). It is synthesized with a single amino acid substitution (alanine substituted by glycine at position 2), rendering it resistant to in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and extending its half-life from 7 minutes to approximately 2 hours.

• Cellular Actions: Teduglutide binds to GLP-2 receptors on subepithelial myofibroblasts, stimulating local release of insulin-like growth factor-1 (IGF-1), keratinocyte growth factor (KGF), and endothelial nitric oxide. This cascades into:
  1. Marked crypt cell proliferation and significant inhibition of enterocyte apoptosis.
  2. Increase in villus height and crypt depth, expanding the physical absorptive surface area.
  3. Upregulation of intestinal nutrient and fluid transporters (SGLT-1, GLUT2).
  4. Slowing of gastrointestinal transit and improvement in mesenteric blood flow.

Clinical Indications & Weaning

• Indication: Indicated for adult and pediatric patients with Short Bowel Syndrome who are dependent on parenteral support (PN/IV fluids) following a period of natural intestinal adaptation (typically $\ge 12\text{ months}$ post-resection).
• Clinical Outcome: Clinical trials demonstrate that daily subcutaneous teduglutide ($0.05\text{ mg/kg/day}$) achieves a $\ge 20\%$ reduction in weekly parenteral support volume in the vast majority of patients, with a significant proportion achieving complete independence from parenteral nutrition.
• Safety Monitoring: Because GLP-2 promotes mucosal hyperplasia, it carries a potential risk of accelerating occult neoplastic growth. Patients must undergo a complete colonoscopy to evaluate and resect polyps prior to initiating therapy, with surveillance repeat colonoscopy recommended at 1 to 2 years.